What is the significance of posttreatment control of HIV infection vis-à-vis functional cure

AIDS

Volumn 28, Issue 4, 2014, Pages 603-605

  Vanham, Guido ^a   Buvé, Anne ^a   Florence, Eric ^a   Seguin Devaux, Carole ^b   Sáez Cirión, Asier ^c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 84895068716     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000147     Document Type: Note

References (22)

1. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.
2. Walker BD. Elite control of HIV Infection: Implications for vaccines and treatment. Top HIV Med 2007; 15:134-136.
3. Saez-Cirion A, Pancino G. HIV controllers: A genetically determined or inducible phenotype Immunol Rev 2013; 254:281-294.
4. Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, et al. Immune and viral correlates of Secondary Viral Control after treatment interruption in chronically HIV-1 infected patients. PLoS One 2012; 7:e37792.
5. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 2013; 9:e1003211.
6. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
7. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): A randomised trial. Lancet 2006; 367:1981-1989.
8. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
9. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:e36.
10. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, et al. Antiretroviral therapy in acute and recent HIV infection: A prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23:1987-1995.
11. Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One 2011; 6:e27463.
12. Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: The randomized primo-SHM trial. PLoS Med 2012; 9:e1001196.
13. Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013; 368:207-217.
14. Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012; 7:e43754.
15. Steingrover R, Pogany K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008; 22:1583-1588.
16. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
17. Goujard C, Girault I, Rouzioux C, Lecuroux C, Deveau C, Chaix ML, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy. Antivir Ther 2012; 17:1001-1009.
18. Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252-1255.
19. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4R T cells. Nat Med 2003; 9:727-728.
20. Lewin SR, Rouzioux C. HIV cure and eradication: How will we get from the laboratory to effective clinical trials AIDS 2011; 25:885-897.
21. Routy JP, Boulassel MR, Nicolette CA, Jacobson JM. Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy. J Med Virol 2012; 84:885-889.
22. Machado C, Rios-Villegas MJ, Galvez-Acebal J, Dominguez-Castellano A, Fernandez-Cuenca F, Palomo V, et al. Long-term outcome of patients after a single interruption of antiretroviral therapy: A cohort study. BMC Res Notes 2012; 5:578.